Recent Highlights:
Achieved total revenue of $79.2 million for the three months ended December 31, 2021, increasing 35% over prior year fourth quarter
Delivered full year revenue of $296.4 million, an increase of 54% compared with full year 2020 revenue
Provided approximately 41,900 AlloSure and AlloMap patient results in the fourth quarter, growing 67% from prior year quarter. Full year 2021 AlloSure and AlloMap testing volumes grew year over year by 94% to approximately 153,000 tests
Generated positive clinical data with the announcement of the publication of multiple studies, including the ADMIRAL and ALARM studies
Launched AlloSure Lung testing service and processed approximately 700 tests in the fourth quarter
Completed acquisitions of MedActionPlan and The Transplant Pharmacy, adding medication adherence capabilities to our offerings
2022 Guidance
For the full year 2022, CareDx expects revenue to be in the range of $330 million to $350 million.
https://finance.yahoo.com/news/caredx-reports-fourth-quarter-full-210100737.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.